EISSN 2684-4907

5 YEAR IMPACT FACTOR 0.2 SCOPUS CITESCORE 0.6 IMPACT FACTOR 0.2

B-ENT

20 109 2024

HIGHLY CITED ARTICLES

COVID-19 and olfactory dysfunction - an ENT perspective to the current COVID-19 pandemic

By: Vroegop, AV; Eeckels, AS; Van Rompaey, V; et al.

Prioritizing otological surgery during the COVID-19 pandemic

By: Topsakal, V; Van Rompaey, V; Kuhweide, R; et al.

Tracheostomy and personal protective equipment (PPE) in the midst of the COVID-19 pandemic

By: Faris, C; Deben, K; Van Haesendonck, G; et al.

Anosmia and COVID-19 in south Lombardy: description of the first cases series in Europe

By: Capelli, M and Gatti, P

Evaluation of nasal function in patients with COVID-19: nasal secretion, nasal clearance, and SNOT-22 score

By: Baki, A; Damlaca, S; Yildiz, M; et al.

Challenges in pediatric otolaryngology in the COVID-19 pandemic: insights from current protocols and management strategies

By: Van der Poel, N; Mansbach, AL; Loundon, N; et al.

Minimal outcome measurements in pediatric cochlear implant users: a consensus paper

By: Mertens, G; Hofkens, A; Van de Heyning, P; et al.

Is an increase in the depth of the olfactory fossa caused by excessive vertical facial growth? A radiological study ocr

By: Calvo-Henriquez, C; Ruano-Ravina, A; Martinez-Capoccioni, G; et al.

Medical treatment for vertigo

C. Desloovere ¹

Author Affiliation(s)

1.

Department of Ear, Nose and Throat disease, University Hospital, Catholic University of Leuven, Belgium

B-ENT 2008; 4: Supplement 59-62

Keywords : Vertigo; drug therapy

Read: 617 Downloads: 440 Published: 20 February 2020

Volume 4, Issue -1, January 2008

Previous Article

Medical treatment for vertigo. An overview of the medical treatment options currently available for vertigo in Belgium is given. There are three sections: drug treatment for acute unilateral vestibular loss, Ménière’s disease and motion sickness. The pharmacological properties, contra-indications, side-effects and dosage are discussed for each drug.

Files